Pharma Mar Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Pharma Mar wird ein jährliches Gewinn- und Umsatzwachstum von 56.9% bzw. 26% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 57% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 35.4% betragen.

Wichtige Informationen

56.9%

Wachstumsrate der Gewinne

57.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.4%
Wachstumsrate der Einnahmen	26.0%
Zukünftige Eigenkapitalrendite	35.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Oct 16

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19

Gewinn- und Umsatzwachstumsprognosen

BME:PHM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	299	121	116	125	4
12/31/2025	188	57	60	71	5
12/31/2024	162	-1	0	23	5
9/30/2024	167	1	-18	2	N/A
6/30/2024	159	-2	-30	-10	N/A
3/31/2024	162	2	-35	-12	N/A
12/31/2023	158	1	-29	-13	N/A
9/30/2023	168	14	-29	-13	N/A
6/30/2023	175	21	-14	-1	N/A
3/31/2023	177	29	N/A	N/A	N/A
12/31/2022	196	49	29	38	N/A
9/30/2022	235	79	N/A	N/A	N/A
6/30/2022	233	85	41	48	N/A
3/31/2022	232	91	N/A	N/A	N/A
12/31/2021	230	93	18	26	N/A
9/30/2021	188	63	N/A	N/A	N/A
6/30/2021	200	67	19	24	N/A
3/31/2021	222	91	113	117	N/A
12/31/2020	270	137	276	279	N/A
9/30/2020	246	147	264	270	N/A
6/30/2020	214	124	255	259	N/A
3/31/2020	166	72	161	165	N/A
12/31/2019	86	-9	-28	-24	N/A
9/30/2019	136	-27	-24	-23	N/A
6/30/2019	84	-37	-12	-12	N/A
3/31/2019	154	-24	-24	-22	N/A
12/31/2018	109	-17	-19	-17	N/A
9/30/2018	189	-16	-23	-20	N/A
6/30/2018	128	-20	N/A	-22	N/A
3/31/2018	179	-26	N/A	-19	N/A
12/31/2017	159	-28	N/A	-1	N/A
9/30/2017	182	-22	N/A	4	N/A
6/30/2017	186	-18	N/A	9	N/A
3/31/2017	184	-19	N/A	13	N/A
12/31/2016	181	-24	N/A	-8	N/A
9/30/2016	187	-18	N/A	N/A	N/A
6/30/2016	188	-10	N/A	5	N/A
3/31/2016	190	-7	N/A	N/A	N/A
12/31/2015	194	7	N/A	11	N/A
12/31/2014	175	13	N/A	23	N/A
12/31/2013	74	12	N/A	74	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PHMDas prognostizierte Gewinnwachstum (56.9% pro Jahr) liegt über der Sparquote (1.8%).

Ertrag vs. Markt: PHMDie Erträge des Unternehmens (56.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (9% pro Jahr).

Hohe Wachstumserträge: PHMEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: PHMDie Einnahmen des Unternehmens (26% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Spanish (4.9% pro Jahr).

Hohe Wachstumseinnahmen: PHMDie Einnahmen des Unternehmens (26% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PHMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (35.4%)

Pharma Mar Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates have been downgraded.

Price target increased by 10% to €71.33

Price target increased by 17% to €60.33

Consensus EPS estimates increase by 149%

Consensus EPS estimates fall by 76%

Consensus EPS estimates fall by 29%

Recent updates

Consensus EPS estimates have been downgraded.

Price target increased by 10% to €71.33

Third quarter 2024 earnings released

Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024

Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%

Price target increased by 17% to €60.33

New major risk - Share price stability

Second quarter 2024 earnings released

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024

Consensus EPS estimates increase by 149%

Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Consensus EPS estimates fall by 76%

Dividend of €0.53 announced

Consensus EPS estimates fall by 29%

New major risk - Dividend sustainability

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: €0.06 (vs €2.73 in FY 2022)

Consensus EPS estimates fall by 78%

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Price target decreased by 9.1% to €49.83

Consensus EPS estimates fall by 13%, revenue upgraded

New major risk - Earnings quality

Second quarter 2023 earnings released

Price target decreased by 7.4% to €54.83

Consensus EPS estimates fall by 35%

Price target decreased by 9.7% to €57.17

Consensus EPS estimates fall by 22%

Pharma Mar, S.A., Annual General Meeting, May 31, 2023

Price target decreased by 11% to €61.20

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 23%, revenue upgraded

Now 20% undervalued after recent price drop

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 21%

Price target decreased by 7.6% to €71.03

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Consensus EPS estimates fall by 17%, revenue upgraded

Now 20% undervalued

Pharma Mar, S.A.(BME:PHM) dropped from Madrid Ibex 35 Index

Now 20% undervalued

High number of new directors

Consensus forecasts updated

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Now 21% undervalued after recent price drop

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

Pharma Mar, S.A. to Report Q2, 2022 Results on Jul 27, 2022

Second quarter 2022 earnings released

High number of new directors

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Upcoming dividend of €0.53 per share

Investor sentiment deteriorated over the past week

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Consensus forecasts updated

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Pharma Mar, S.A. to Report Q4, 2021 Results on Feb 28, 2022